Thus, measures designed to suppress global, or astrocyte‐specific, SLC13A3 expression and NaDC3 activity in infants and children with Canavan disease may prove useful in limiting [NAAB] elevation and preventing or ameliorating their neurological deficits, but might also increase their risk for developing reversible leukoencephalopathy. Here, SLC13A3 is linked to Canavan disease.